V1RE8 Inhibitors
V1RE8 inhibitors are a category of chemical agents engineered to selectively bind to the V1RE8 protein, a specific biological molecule that plays a role in certain cellular processes. The development of these inhibitors is rooted in a deep understanding of V1RE8's structure and operational mechanisms. By attaching to the active site or another critical region of V1RE8, these inhibitors are able to modulate its interaction with other molecules within the cell. The architecture of V1RE8 inhibitors is typically intricate, incorporating various functional groups and stereocenters that enhance their binding affinity and selectivity. The synthesis of these compounds is an elaborate process, necessitating meticulous control over reaction parameters to ensure the production of the desired compound with the appropriate attributes.
The creation and refinement of V1RE8 inhibitors is a concerted scientific endeavor, integrating expertise from several domains such as chemistry, biochemistry, and structural biology. Chemists in this field design new inhibitors and refine existing ones by iterating through synthesis and analysis, gauging how structural changes affect molecular interaction with V1RE8. Structural biologists contribute by elucidating the three-dimensional arrangement of V1RE8, both in isolation and when complexed with inhibitors. Techniques like X-ray crystallography and NMR spectroscopy are commonly employed to obtain detailed structural data, which is crucial for understanding how inhibitors fit and function at the molecular level. The dynamic between the precise shape of the inhibitors and the V1RE8 protein's structure is central to the design process. Additionally, properties such as solubility and stability of the inhibitors are fine-tuned to ensure optimal interaction with V1RE8. The aim of this meticulous optimization is to achieve a high degree of specificity in the interaction with the target molecule, thereby reducing non-specific binding that could lead to undesired effects.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. V1RE8 activity is dependent on the cell cycle progression, which is regulated by CDKs. Inhibition of CDK4/6 by Palbociclib leads to cell cycle arrest at G1 phase, thereby reducing the activity of V1RE8 linked to cell cycle-dependent processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). V1RE8 is involved in the PI3K/AKT signaling pathway, and inhibition of PI3K by LY294002 leads to reduced AKT phosphorylation and activity, subsequently decreasing V1RE8 signaling that is modulated through this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTORC1 complex. V1RE8 is involved in the mTOR signaling pathway, and inhibition of mTOR by Rapamycin leads to a decrease in protein synthesis and cell growth, which are processes regulated by V1RE8. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that blocks the MAPK/ERK pathway. V1RE8 is implicated in the MAPK/ERK signaling, and inhibition of MEK by Trametinib leads to reduced ERK activation, resulting in decreased activity of V1RE8 that is modulated through this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that impedes the MAPK/ERK signaling cascade. By inhibiting MEK, U0126 prevents the activation of ERK, thus reducing the V1RE8 activity associated with this pathway. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is a selective inhibitor of the EGFR kinase with a particular efficacy against EGFR mutations. V1RE8 can be involved in EGFR signaling, and inhibition by WZ4002 may lead to reduced V1RE8 activity in pathways reliant on EGFR signaling. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Vemurafenib is a BRAF inhibitor that specifically targets the BRAF V600E mutation. As V1RE8 signaling can be downstream of BRAF activity, the use of Vemurafenib leads to decreased V1RE8 function in cells with this mutation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Since V1RE8 may interact with Src family kinases in certain signaling pathways, inhibition by Dasatinib could lead to decreased V1RE8 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to the depletion of calcium stores and induces ER stress. V1RE8, which may be involved in calcium signaling or ER stress response, can have decreased activity due to the perturbation of calcium homeostasis caused by Thapsigargin. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins and induce apoptosis. If V1RE8 is involved in protein degradation processes, Bortezomib can indirectly reduce its functional activity through the disruption of proteasome function. | ||||||